Evidence map›Paper›PMID 37885772›Full record

ArticleVaccine: X2023

Weaker SARS-CoV-2 vaccine responses in nonalcoholic fatty liver disease with advanced liver fibrosis.

David Hakimian, Johnny Amer, Alaa Jammal, Asher Shafrir, Yael Milgrom, Mohammad Masarowah, Wadi Hazou, Yuval Ishay, Ashraf Imam, Adi Francis and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

David HakimianHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Johnny AmerHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Alaa JammalHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Asher ShafrirHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Yael MilgromHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Mohammad MasarowahHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Wadi HazouHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Yuval IshayHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Ashraf ImamHadassah Medical Center, Department of Surgery, Jerusalem, Israel.
Adi FrancisHadassah Medical Center, Cardiac Care Unit, Holy Family Hospital, Bar-Ilan University, Nazareth, Israel.
Abed KhalailehHadassah Medical Center, Department of Surgery, Jerusalem, Israel.
Rifaat SafadiHadassah Medical Center, Liver insitute, Hadassah-Hebrew University Medical Center, Israel.
Hadassah Medical Center · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: SARS-CoV-2 vaccine responses that could harbor potential risks to chronic liver diseased patients. Aims: To assess immune response following Pfizer's SARS-CoV-2 vaccine in patients with different liver fibrosis severities of nonalcoholic fatty liver disease (NAFLD). Methods: Clinical and histological (NAS-score and fibrosis stage) characteristics of NAFLD patients before vaccine were correlated with serologic vaccine responses of two doses of the BNT162b2. Serum SARS-CoV-2 spike immunoglobulins (anti-S) were assessed on day seven following immunization (Liaison assay). Results: The mean-age of patients (n = 157) was 56.9 ± 13.2 years (46.5 % males). 94.8 % had a positive response (anti-S levels ≥ 19 AU/ml). The anti-S cutoff of 200 AU/ml used to separate strong Conclusion: Advanced liver fibrosis (assessed by histology, Fib-4, or Fibroscan) is a risk factor for lower response to Pfizer's BNT162b2 vaccine, and patients should be prioritized for the vaccine booster against SARS-CoV-2.

Indexed as

FibroscanLiver fibrosis stageNAS scorePfizer's mRNA SARS-CoV-2 vaccineSerum SARS-CoV-2 spike immunoglobulins

Identifiers

PMID37885772
PMCPMC10598407
OpenAlexW4387569494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.